How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

445 results for

Wart Immune Therapy

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. HIV Course

From Related Chapters II. Background: Natural History of HIV Disease Total duration from initial to No treatment: 10 years Early therapy: May approach normal Active immune response after infection: 2.1 months Primary infection usually asymptomatic in 30-50% Initial infection with single Evolves into 15-20 distinct viral variants gains access to CD4 cells via sequential binding CD4 receptor via sequential binding with CD4 receptor in combination with CCR5 or CXCR4 co-receptors Over time: CD4 cell (...) received no therapy Course over following 18-24 months Risk of occult infection or death: <5% Slow decline in s (40 to 80 cells/year) VI. Staging: Intermediate Disease (CD4 Count 200 - 500 cells) HIV related disorders Pronounced , Recurrent Infection Recurrent Infection Pruritic Recurrent s Anogenital ulcers or warts Complications Atypical in this stage Management therapy is continued from prior stages Course (Untreated) over following 18-24 months Risk of occult infection or death: 20-30% Treatment

2018 FP Notebook

142. Vaginal Cancer Treatment (PDQ®): Health Professional Version

is usually treated.[ ] Imiquimod cream 5%, an immune stimulant used to treat genital warts, is an additional topical therapy that has a reported complete clinical response rate of 50% to 86% in small case series of patients with multifocal high-grade HPV-associated VAIN 2 and 3.[ ] However, it is investigational, and it may have only short-lived efficacy.[ ] Current Clinical Trials Use our to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location (...) cases: 5,350. Deaths: 1,430. Carcinomas of the vagina are uncommon tumors comprising about 1% of the cancers that arise in the female genital system.[ , ] Early-stage tumors are often curable with local modality therapies, but there is no standard treatment of proven efficacy for metastatic disease. A large proportion (30%–50%) of women with vaginal carcinomas have had a previous hysterectomy for benign, pre-malignant, or malignant disease.[ , ] The American Joint Committee on Cancer (AJCC) staging

2015 PDQ - NCI's Comprehensive Cancer Database

143. HIV infection and AIDS

— refer to an HIV specialist. Viral hepatitis co-infection — refer to an HIV specialist. : Genital and perianal warts — refer to a genito-urinary medicine (GUM) clinic unless the person is responding well to topical therapy. See the CKS topic on for further information. Anal intra-epithelial and anal squamous cell carcinomas are more common in people with HIV so if there are any atypical features, refer the person to a colorectal specialist. All women with newly diagnosed HIV should have initial (...) HIV infection and AIDS HIV infection and AIDS - NICE CKS Clinical Knowledge Summaries Share HIV infection and AIDS: Summary The Human Immunodeficiency Virus (HIV) is a retrovirus that preferentially infects and destroys cells of the immune system, in particular the CD4 cells (a class of T lymphocyte, also known as T helper cells). There are 2 main types of HIV: HIV-1 (the predominant type in the UK) is highly virulent and is found worldwide. HIV-2 is found mainly in West Africa but has also

2015 NICE Clinical Knowledge Summaries

144. Cervical cancer and HPV

bleeding. Have persistent or unexplained vaginal bleeding after cessation of hormone replacement therapy for 6 weeks. Refer premenopausal women to gynaecology or genitourinary medicine clinic, who have: Persistent intermenstrual bleeding, post-coital bleeding, or blood-stained vaginal discharge, and: Polyp, ectropion, cervicitis, or warts. Infection has been excluded or infection had been treated, but the bleeding has continued for 6–8 weeks post treatment. Consider urgent referral (within 2 weeks (...) , 11, 16, and 18 [ ]. It is highly effective [100% (95% CI: 90.5– 100)] at preventing pre-cancerous lesions associated with HPV types 16 and 18. It is also almost 100% effective in preventing genital warts associated with HPV types 6 and 11. Both the bivalent and the quadrivalent vaccines provide some cross-protection against other HPV genotypes not included in the vaccine [ ; ]. Protection from HPV is maintained for at least 10 years after immunization [ ]. Scenario: Management Scenario

2014 NICE Clinical Knowledge Summaries

145. Has Western medicine lost its soul?

to illness. Naturopaths believe that such symptoms as warts are the result of toxins in the body, and an immune system that is not running efficiently. They may prescribe treatments such as colonic irrigation, alongside a program of healthy eating to raise the general level of health. (Gods of HTML protect me) to post comments By Johnny (not verified) on 23 Jun 2015 to post comments By zebra (not verified) on 23 Jun 2015 to post comments By Johnny (not verified) on 23 Jun 2015 to post comments (...) to "Western medicine" and looked at his arguments: Today, someone who needs attention for a health matter can seek conventional “Western” medicine or opt to receive a “holistic” treatment from the realm of so-called alternative medicine. For most people, there is a clear distinction between the two. Sure, some licensed physicians claim to provide holistic care, but this usually means that they might add an alternative form of therapy to standard treatment, or perhaps that they strive to be exceptionally

2015 Respectful Insolence

146. Gardasil 9 - human papillomavirus 9-valent vaccine (recombinant, adsorbed)

procedure falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 19 September 2013 The applicant applied for the following indication: Gardasil 9 is indicated for active immunization from the age of 9 years against the following HPV diseases: • cervical cancer and premalignant cervical lesions • vulvar and vaginal cancers and premalignant vulvar and vaginal lesions • external genital warts (...) doses should be given within a 1-year period. Gardasil 9 is indicated for active immunization from the age of 9 years against the following HPV diseases caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52, 58: (1) cervical cancer and premalignant cervical lesions; (2) vulvar and vaginal cancers and premalignant vulvar and vaginal lesions; (3) premalignant anal lesions and anal cancers; (4) external genital warts. Quality aspects 2.2.1. Introduction Papillomaviruses, which are small, non-enveloped

2015 European Medicines Agency - EPARs

147. Triumeq - abacavir sulfate / dolutegravir sodium / lamivudine

after an interruption of Triumeq therapy”). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing (see section 4.4 and 4.8)”. The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC - complete and independent application. The application submitted is composed of administrative information, complete quality data, non- clinical (...) of 15; at present around 2.5 million people are newly infected each year. Worldwide, around 50% of these infected are women, which differs from some western world regions where males are still those mainly infected. In western/central Europe around 1 million people are infected; in the US around 1.5 million. Antiretroviral therapy has led to a dramatic reduction in mortality and morbidity in treated HIV-infected individuals. Indeed, those able to get adequate and continuous treatment might expect

2014 European Medicines Agency - EPARs

148. Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections Ongoing alcohol or drug abuse within the past 12 months History of genital warts or a positive test for HPV Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact (...) to any vaccine component, including aluminum, yeast, or BENZONASE™ Received immune globulin or blood-derived products in the past 6 months or plans to receive any before Month 7 of the study History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition

2015 Clinical Trials

149. Use of Candida antigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience. (PubMed)

Use of Candida antigen injections for the treatment of verruca vulgaris: A two-year mayo clinic experience. Common warts (verruca vulgaris) are one of the most common problems encountered in dermatology and may present a difficult treatment dilemma, as no particular therapy has demonstrated complete efficacy. Intralesional injection of purified Candida antigen has produced impressive treatment results in small prospective and retrospective studies and is thought to produce its effect through (...) stimulation of a cell-mediated immune response. We report a retrospective study of adult and pediatric patients treated with Candida antigen therapy in clinical practice. Of the 100 patients treated, 80% responded to therapy: 39% demonstrated a complete response and 41% demonstrated a partial response. In addition, 6 out of 7 immunocompromised patients who were treated demonstrated a partial or complete response. Injections were generally well-tolerated and adverse events were minimal and short-lived. Our

2015 Journal of Dermatological Treatment

150. On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

plus purine or folic acid analogues; iv) alternate therapy, such as phototherapy, fumaric acid, mesalazine. The last group additionally included patients that were without any therapy. Information about duration and severity of illness, current and former disease-related medical treatment, smoking habits and sexual history with emphasis on preexisting human papillomavirus (HPV) infection, including anogenital warts or previous abnormal cervical cytology, and HPV vaccination status were obtained (...) (IBD), who received either Tumor necrosis factor-alpha (TNF-Alpha) inhibitors or alternates (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) for their underlying disease were included. Patients were assigned to the following subgroups according to their current therapy for ≥ 6 months: i) TNF-alpha inhibitor monotherapy; ii) monotherapy with purine or folic acid analogues, such as azathioprin, 6-mercaptopurine, or methotrexate iii) combination therapy with TNF-alpha blocker

2015 Clinical Trials

151. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis-Untapped Potential in the Tumor Microenvironment. (PubMed)

, offering proof of concept. Other antagonists are in preclinical and clinical development. Recent evidence demonstrates that inhibiting CXCR4 signaling restores sensitivity to CTLA-4 and PD-1 checkpoint inhibitors, creating a new line for investigation. Targeting the CXCR4-CXCL12 axis thus offers the possibility of affecting CXCR4-expressing primary tumor cells, modulating the immune response, or synergizing with other targeted anticancer therapies.©2015 American Association for Cancer Research. (...) Molecular Pathways: Targeting the CXCR4-CXCL12 Axis-Untapped Potential in the Tumor Microenvironment. Evidence suggests that the CXC-chemokine receptor-4 pathway plays a role in cancer cell homing and metastasis, and thus represents a potential target for cancer therapy. The homeostatic microenvironment chemokine CXCL12 binds the CXCR4 and CXCR7 receptors, activating divergent signals on multiple pathways, such as ERK1/2, p38, SAPK/JNK, AKT, mTOR, and the Bruton tyrosine kinase (BTK

Full Text available with Trip Pro

2015 Clinical Cancer Research

152. Position Statement: the management of patients with physical and psychological problems in primary care - a practical guide

for depression, and the Improving Access to Psychological Therapies (IAPT) programme, which aims to improve delivery of talking treatments to service users with mental health problems. Multidisciplinary liaison psychiatry services, which have been traditionally hospital-based, can provide valuable community support and training for staff, including GPs, active case managers and other primary care professionals. Treatment can also be offered for individuals with severe and complex needs (if appropriate (...) catecholamine and corticosteroid release, which produces symptoms such as palpitations, muscular tension and a complex but negative effect on the immune system via cytokine and neuropeptide transmissions. Another individual experiencing the same loss but whose world is socially richer and who has more resilient coping mechanisms will also grieve and suffer, but can draw on their own sense of independent self-esteem, will use expression of feelings to others to a greater extent and may also have more insight

2009 Royal College of General Practitioners

153. The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

not respond properly to fight the virus. Researchers have discovered some reasons why a person may not be able to clear an infection caused by a virus. Some persons have changes in the genes that involve the immune system that result in the inability to properly control infection with a particular virus. Identifying changes in genes that involve the immune system should help scientists better understand how the immune system works to protect people from infection and may help develop new therapies (...) if identified immune defects are hereditary. Design: Prior to the study, the participant's doctor will give researchers the details of the infection, along with medical records for review. Eligible participants will be invited to the NIH Clinical Center for a full evaluation as an outpatient or inpatient. At the Clinical Center, participants will be treated with the best available therapy for the particular viral infection, and researchers will monitor how the infection responds to the treatment

2009 Clinical Trials

154. Topical or Ablative Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Squamous Intraepithelial Lesions

Intervention/treatment Phase Anal Cancer High-grade Squamous Intraepithelial Lesion HIV Infection Human Papilloma Virus Infection Drug: imiquimod Drug: fluorouracil Device: infrared photocoagulation therapy Device: thermal ablation therapy Device: laser therapy Other: clinical observation Other: laboratory biomarker analysis Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 5058 participants Allocation: Randomized Intervention (...) topical or ablative treatment at the discretion of the clinician. Patients receiving topical treatment apply imiquimod intra-anally, peri-anally or both thrice weekly for up to 16 weeks, fluorouracil twice daily for 5 days every 2 weeks for up to 16 weeks, or trichloroacetic acid every 3 weeks up to 12 weeks. Patients receiving ablative treatment using infrared photocoagulation therapy, hyfrecation/electrocautery (thermal ablation therapy), or laser therapy. Patients may undergo excision under

2014 Clinical Trials

155. Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990

on the specific type of primary immune deficiency diseases, there are effective treatments, including antibiotics, cellular therapy and gene therapy, but studies of large numbers of patients are needed to determine the full range of causes, natural history, or the best methods of treatment for long term success. This multicenter study combines retrospective, prospective and cross-sectional analyses of the transplant experiences for patients with WAS who have already received HCT since 1990, or who (...) and Infectious Diseases (NIAID): Wiskott-Aldrich Syndrome Hematopoietic Stem Cell Transplantation Genetic Therapy Additional relevant MeSH terms: Layout table for MeSH terms Syndrome Wiskott-Aldrich Syndrome Disease Pathologic Processes Blood Coagulation Disorders, Inherited Blood Coagulation Disorders Hematologic Diseases Hemorrhagic Disorders Lymphopenia Leukopenia Leukocyte Disorders Genetic Diseases, Inborn Genetic Diseases, X-Linked Immunologic Deficiency Syndromes Immune System Diseases

2014 Clinical Trials

156. Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)

preclude participation in the study. Additional Criteria for Diabetic Subjects: Abnormal liver function tests at screening. For T2DM subjects: ALT or AST >=2.5 x ULN or alkaline phosphatase or total bilirubin >=1.5 x ULN at screening. Current regular use of or anticipated requirement for anti-inflammatory medications (e.g. Non-steroidal anti-inflammatory drugs [NSAIDs] including low dose aspirin, glucocorticoids) and immune-modulatory therapies during the study. Unable to refrain from the use of non (...) )/mL (<147 picomoles per liter [pmol/L]) is confirmatory]. [Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods listed in the protocol if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks should elapse between the cessation of therapy and the blood draw

2014 Clinical Trials

157. Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)

, and Blood Institute (NHLBI) National Institute of Dental and Craniofacial Research (NIDCR) National Institute on Alcohol Abuse and Alcoholism (NIAAA) Tulane University School of Medicine Information provided by (Responsible Party): George Seage, Harvard School of Public Health Study Details Study Description Go to Brief Summary: This is a prospective cohort study designed to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection (...) as they transition into adulthood. A group of perinatally HIV-exposed, -uninfected (PHEU) young adults from a similar sociodemographic background and age distribution will be enrolled for comparison. Condition or disease HIV/AIDS Detailed Description: AMP Up aims to define the impact of HIV infection and antiretroviral therapy (ART) on young adults with perinatal HIV infection as they transition into adulthood. A group of perinatally HIV-exposed, -uninfected (PHEU) young adults from a similar sociodemographic

2014 Clinical Trials

158. Nasopharyngeal Cancer, Childhood

trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with therapy that is currently accepted as standard. Most of the progress made in identifying curative therapy for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the . Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality (...) decreased by more than 50%.[ ] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary on for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.) Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[ ] The U.S. defines

2012 PDQ - NCI's Comprehensive Cancer Database

159. Multiple Endocrine Neoplasia, Childhood

trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with therapy that is currently accepted as standard. Most of the progress made in identifying curative therapy for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the . Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality (...) decreased by more than 50%.[ ] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary on for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.) Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[ ] The U.S. defines

2012 PDQ - NCI's Comprehensive Cancer Database

160. Mesothelioma, Childhood

for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with therapy that is currently accepted as standard. Most of the progress made in identifying curative therapy for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the . Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased (...) by more than 50%.[ ] Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment. (Refer to the PDQ summary on for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.) Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[ ] The U.S. defines a rare

2012 PDQ - NCI's Comprehensive Cancer Database

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>